Trademarkia Logo

Canada

C$
Trademark Search in Canada
BerGenBio

View On IC.GC.CA

BerGenBio
APPROVED

on 30 Jan 2025

Last Applicant/ Owned by

BerGenBio ASA

P.O. Box 2324 MøllendalN-5867 Bergen

NO

Serial Number

2158377 filed on 22nd Oct 2021

Correspondent Address

BENNETT JONES LLP

4500 BANKERS HALL EAST855 - 2ND STREET S.W.CALGARY

ALBERTA

CA

T2P4K7

BerGenBio

Trademark usage description

chemicals, chemical compounds, biochemicals and biologic compounds for the experimental production of drugs, pharmaceutical products and biotechnologi Read More

Vienna Information

26 . 5 . 1

One polygonUn polygone

26 . 5 . 2

Two polygons, one inside the other (except 26.5.10 and 26.5.11)Deux polygones, l'un dans l'autre (excepté 26.5.10 et 26.5.11)

26 . 5 . 4

Several polygons, juxtaposed, joined or intersectingPlusieurs polygones, juxtaposés, accolés ou se coupant

26 . 5 . 9

Polygons containing one or more circles or ellipsesPolygones contenant un ou plusieurs cercles ou ellipses

26 . 5 . 24

Polygons with dark surfaces or parts of surfacesPolygones avec surface ou partie de la surface foncée

26 . 1 . 1

CirclesCercles

26 . 1 . 6

Several circles or ellipses, juxtaposed, tangential or intersectingPlusieurs cercles ou ellipses, juxtaposés, tangents ou se coupant

26 . 1 . 24

Circles or ellipses with dark surfaces or parts of surfacesCercles ou ellipses avec surface ou partie de la surface foncée

26 . 5 . 26

Polygons with cutout areasPolygones avec des zones découpées

26 . 11 . 14

Dotted lines or bandsLignes ou bandes pointillées

25 . 7 . 1

Surfaces or backgrounds covered with repeated geometrical figures or designsSurfaces ou fonds couverts de figures ou de motifs géométriques répétés

25 . 7 . 6

Surfaces or backgrounds covered with circles or ellipsesSurfaces ou fonds couverts de cercles ou d'ellipses

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

Classification Information

Class [001]
Chemicals, chemical compounds, biochemicals and biologic compounds for the experimental production of drugs, pharmaceutical products and biotechnological preparations; chemicals, chemical compounds, biochemicals and biologic compounds for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely for the diagnosis and treatment of cancers, namely lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; chemicals, chemical compounds, biochemicals and biologic compounds for use in the development and manufacture of drugs and pharmaceutical products, namely drugs and pharmaceutical products that target axl, akt3 and other genes, proteins, kinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely for the diagnosis and treatment of cancers, namely lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely for the diagnosis and treatment of cancers, namely lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for use in the development and manufacture of drugs and pharmaceutical products, namely drugs and pharmaceutical products that target axl, akt3 and other genes, proteins, kinases and enzymes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific and industrial purposes, and for use in laboratories and in research; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely for the diagnosis and treatment of cancers, namely lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical products, namely drugs and pharmaceutical products that target axl, akt3 and other genes, proteins, kinases and enzymes; proteins for use in kinase inhibiting technology [other than for medical use]

Classification kind code

11

Class [005]
Drugs for medical purposes, drugs and pharmaceutical products, namely for treatment of cancers, namely lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; drugs and pharmaceutical products for use in oncology;

Classification kind code

11

Class [042]
Drug discovery and drug development services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific services related to the development of diagnostic products and services, namely relating to the treatment of cancers, namely lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapy, targeted cancer therapy and immuno-oncology drugs; research and development services in the field of antibodies, small molecules and proteins; conducting or providing research and development services for others in the field of antibody and small molecule technology; research, development and engineering of antibodies, small molecules and proteins, namely anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory services relating to the production of antibodies, small molecules and proteins, namely anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodies, small molecules and proteins for the treatment of patients; information, consultancy and advisory services related to the aforesaid.

Classification kind code

11

Mark Details

Serial Number

2158377

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 4th May 2023		Search Recorded
Submitted for opposition 20
on 4th May 2023		Examiner's First Report
Submitted for opposition 135
on 2th Feb 2023		Amendment to Application
Submitted for opposition 256
on 7th Nov 2022		Notification of Possible Opposition Sent
Submitted for opposition 48
on 27th Jan 2022		Agent Changed
Submitted for opposition 257
on 6th Jan 2022		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 5th Jan 2022		Created
Submitted for opposition 31
on 5th Jan 2022		Formalized
Submitted for opposition 30
on 22nd Oct 2021		Filed
Submitted for opposition 228
on 22nd Oct 2021		International Registration